Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jan;29(1):19–25. doi: 10.1111/j.1365-2125.1990.tb03597.x

Haemodynamic and pharmacokinetic study of intravenous fenoldopam in patients with hepatic cirrhosis.

P Vlavianos 1, R J Polson 1, A Settin 1, J Glover 1, D Westaby 1, R Williams 1
PMCID: PMC1380056  PMID: 1967532

Abstract

1. The effect of intravenous fenoldopam-an arterial vasodilator-was assessed in twelve patients with cirrhosis and portal hypertension. Six patients had compensated (Grade A or B Child-Pugh classification) and six decompensated (Grade C) liver disease. 2. A significant dose dependent reduction in systemic blood pressure with a concomitant fall in systemic vascular resistance and increase in cardiac index was observed. Estimated portal pressure (WHVP-FHVP) increased (15.4 +/- 3.2 to 19.3 +/- 3.7 mm Hg, P less than 0.05) due to a rise in wedged hepatic venous pressure (24.6 +/- 4.3 to 29.0 +/- 5.8 mm Hg, P less than 0.05). Hepatic blood flow did not change significantly. Similar haemodynamic effects were observed in both compensated and decompensated patients. 3. Fenoldopam plasma clearance and ICG clearance were found to decrease with increasing infusion concentration, indicating possible increase of the intrahepatic shunting. 4. With the observed rise in portal pressure there must be some concern with respect to the long-term use of this drug in patients with previous variceal bleeding.

Full text

PDF
19

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman D. M., Blumberg A. L., McCafferty J. P., Sherman S. S., Weinstock J., Kaiser C., Berkowitz B. Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526. Fed Proc. 1983 Feb;42(2):186–190. [PubMed] [Google Scholar]
  2. Bendtsen F., Henriksen J. H., Becker U., Sørensen T. I. Effect of oral propranolol on splanchnic oxygen uptake and haemodynamics in patients with cirrhosis. J Hepatol. 1987 Oct;5(2):137–143. doi: 10.1016/s0168-8278(87)80564-0. [DOI] [PubMed] [Google Scholar]
  3. Eriksson L. S., Kågedal B., Wahren J. Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis. Am J Med. 1984 May 31;76(5B):66–70. doi: 10.1016/0002-9343(84)90887-8. [DOI] [PubMed] [Google Scholar]
  4. Freeman J. G., Barton J. R., Record C. O. Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis. Br Med J (Clin Res Ed) 1985 Aug 31;291(6495):561–562. doi: 10.1136/bmj.291.6495.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hahn R. A., Wardell J. R., Jr, Sarau H. M., Ridley P. T. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J Pharmacol Exp Ther. 1982 Nov;223(2):305–313. [PubMed] [Google Scholar]
  6. Harvey J. N., Worth D. P., Brown J., Lee M. R. The effect of oral fenoldopam (SKF 82526-J), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br J Clin Pharmacol. 1985 Jan;19(1):21–27. doi: 10.1111/j.1365-2125.1985.tb02608.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Keiding S. Hepatic clearance and liver blood flow. J Hepatol. 1987 Jun;4(3):393–398. doi: 10.1016/s0168-8278(87)80552-4. [DOI] [PubMed] [Google Scholar]
  8. Lautt W. W., Greenway C. V. Conceptual review of the hepatic vascular bed. Hepatology. 1987 Sep-Oct;7(5):952–963. doi: 10.1002/hep.1840070527. [DOI] [PubMed] [Google Scholar]
  9. Ohlstein E. H., Zabko-Potapovich B., Berkowitz B. A. Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526. J Pharmacol Exp Ther. 1984 May;229(2):433–439. [PubMed] [Google Scholar]
  10. Osborne V. L., Randolph W. C. Analysis of SK&F 82526 in plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1983 Jan 21;255:491–496. doi: 10.1016/s0021-9673(01)88304-7. [DOI] [PubMed] [Google Scholar]
  11. Pugh R. N., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646–649. doi: 10.1002/bjs.1800600817. [DOI] [PubMed] [Google Scholar]
  12. Skak C., Keiding S. Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver. 1987 Jun;7(3):155–162. doi: 10.1111/j.1600-0676.1987.tb00336.x. [DOI] [PubMed] [Google Scholar]
  13. Stote R. M., Dubb J. W., Familiar R. G., Erb B. B., Alexander F. A new oral renal vasodilator, fenoldopam. Clin Pharmacol Ther. 1983 Sep;34(3):309–315. doi: 10.1038/clpt.1983.173. [DOI] [PubMed] [Google Scholar]
  14. Tsai Y. T., Lay C. S., Lai K. H., Ng W. W., Yeh Y. S., Wang J. Y., Chiang T. T., Lee S. D., Chiang B. N., Lo K. J. Controlled trial of vasopressin plus nitroglycerin vs. vasopressin alone in the treatment of bleeding esophageal varices. Hepatology. 1986 May-Jun;6(3):406–409. doi: 10.1002/hep.1840060313. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES